Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous bone marrow-derived mesenchymal stromal cells for emphysema
2017-001853-15Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in emphysema comparing Autologous BM-MSC with Placebo (2 arms). Primary endpoints: PECAM-1 (CD31) expression on pulmonary microvascular endothelial cells and Safety and clinical efficacy by carbon monoxide diffusion capacity. Started Apr 2018; status: active.
02
Drugs
autologous bone-marrow mesenchymal stem cells
03
Conditions
emphysema
Beyond the preview
Go deeper on 2017-001853-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001853-15.